Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Comparing Treatment Combinations in Renal Cell Carcinoma

November 28th 2023

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Dr Bupathi on Treating Patients With RCC in Community vs Academic Settings

November 28th 2023

Manojkumar Bupathi, MD, MS, discusses treating patients with renal cell carcinoma in community vs academic settings.

Dr Barata on the Critical Updates for the Treatment of Advanced RCC in 2023

November 27th 2023

Pedro Barata, MD, MSc, discusses the biggest clinical trial updates to emerge for the treatment of patients with advanced renal cell carcinoma from the 2023 International Kidney Cancer Symposium.

Dr Garmezy on the Treatment of Patients With Cancer in the Community Setting

November 22nd 2023

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Dr Zhang on the Evolution of the Use of Belzutifan in RCC

November 22nd 2023

Tian Zhang, MD, MHS, discusses the evolution of the use of belzutifan in renal cell carcinoma, highlighting which key oncologists have been involved in this research.

Dr Tan on the Use of the Signatera™ Assay in RCC

November 22nd 2023

Alan Tan, MD, discusses the ongoing potential utility of circulating tumor DNA in patients with renal cell carcinoma and highlights how this approach is being used in his own practice.

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Dr Ecker on the Investigation of the Microbiome in Pancreatic Cancer

November 17th 2023

Brett L. Ecker, MD, discusses the evaluation of the microbiome in pancreatic cancer, highlighting remaining questions and future steps for research.

Study Shows Feasibility of IO Maintenance After IO/VEGF TKI Response in Previously Untreated Metastatic ccRCC

November 17th 2023

Interrupting combination treatment with axitinib and avelumab and switching to avelumab maintenance after a response at 36 weeks led to a decrease in treatment-related toxicities and delayed tumor progression in previously untreated patients with metastatic clear cell renal cell carcinoma.

Volrustomig Demonstrates Activity in Treatment-Naive Advanced ccRCC

November 16th 2023

Volrustomig demonstrated efficacy when used as frontline treatment in patients with clear cell renal cell carcinoma with a toxicity profile that is consistent with dual checkpoint inhibition.

Imaging and Staging Considerations in Renal Cell Carcinoma

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Research Aims to Make Inroads With CAR T-Cell Therapy in Advanced RCC

November 11th 2023

Although not immediately practice changing, CAR T-cell therapy has the potential to become a standard of care for patients with advanced renal cell carcinoma following progression on checkpoint inhibitors and VEGF inhibitors.

Deeper Understanding of Clonal Hematopoiesis Could Improve Cardiovascular Outcomes for Patients With Kidney Cancer

November 11th 2023

Additional research exploring the association between clonal hematopoiesis and cardiovascular health could help improve outcomes for patients with kidney cancer and identify those at higher risk for experiencing cardiac events.

Cancer Immunity Cycle Could Inform Development of Novel Immune Therapies in RCC

November 11th 2023

Further understanding of the cancer immunity cycle could drive the development of novel immune therapies for patients with renal cell carcinoma.

Treatment Decisions in RCC Could Be Aided by ctDNA

November 11th 2023

Decisions regarding the intensification or de-escalation of treatment, particularly with immunotherapy and TKIs, for patients with renal cell carcinoma could be aided by circulating tumor DNA.

Dr Ramnaraign on Retrospective Data For irAEs in Older Patients With Kidney Cancer

November 11th 2023

Brian H. Ramnaraign, MD, discusses findings from a single-institution review of the incidence of immunotherapy-related toxicities in older patients with kidney cancer.

Dr Tan on the Potential Utility of ctDNA in RCC

November 11th 2023

Alan Tan, MD, discusses the ongoing investigation and potential utility of circulating tumor DNA in patients with renal cell carcinoma.

LITESPARK-013 Data Support RP2D of Belzutifan as Standard Option in Advanced ccRCC

November 11th 2023

Administration of the hypoxia-inducible factor–2α inhibitor belzutifan (Welireg) at the recommended phase 2 dose of 120 mg daily produced comparable toxicities and efficacy outcomes to that of a daily 200-mg dose of the agent in patients with advanced clear cell renal cell carcinoma.

Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC

November 11th 2023

Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.